Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Pharvaris Director Robert Glassman Sells $332K of Stock
Robert Glassman, Director, sold 8,667 shares of Pharvaris N.V. at $38.27 a share, worth $332K in total on Sep 15, 2026. Shares held after the trade: 10,500 (-45.2%).
Evernorth Holdings $30M Debt Financing with NH Investment & Securities Co. as trustee of Kyobo AIM...
Evernorth Holdings Inc. entered into a note purchase agreement to issue $30.0 million in 4.00% Convertible Senior PIK Notes due 2031. The issuance is contingent upon the closing of the company's business combination with Armada Acquisition Corp. II, with proceeds intended for general corporate purposes and XRP ecosystem acquisitions.
Value
$30M
Counterparty
NH Investment & Securities Co. as trustee of Kyobo AIM Corporate Finance General Private Investment Trust No. 3
First Financial Corporation declared a quarterly cash dividend of $0.56 per share. The dividend is payable on October 15, 2026, to shareholders of record as of October 1, 2026.
Hive Digital Technologies Partnership with ProCogia
HIVE Digital's subsidiary BUZZ HPC entered into a strategic partnership with ProCogia to provide end-to-end sovereign AI solutions. ProCogia will procure dedicated GPU capacity from HIVE's Canadian data centers to power its AI products while serving as a preferred services partner for HIVE's clients, with both companies planning a joint go-to-market strategy in the U.S. and Europe.
Caesars Entertainment M&A Deal with Fertitta Gaming Holdco, LLC
Caesars Entertainment provided a status update on its pending merger with Fertitta Gaming Holdco, noting that both parties received a 'Second Request' for information from the FTC, extending the HSR Act waiting period. Additionally, two board members, Jesse Lynn and Ted Papapostolou, resigned from the Board effective immediately as the Icahn Group waived its right to appoint replacements.
PetMed Express has appointed Jeffrey Allen Willard as its new CEO and President, effective September 28, 2026, succeeding interim CEO Leslie C.G. Campbell. Under his employment agreement, Willard will receive an annual base salary of $550,000, a $120,000 signing bonus, and a $50,000 relocation allowance. Additionally, Justin Mennen will succeed Campbell as Chair of the Board following her retirement.
Faraday Future Intelligent Electric Nasdaq/NYSE Compliance Notice
Faraday Future reported that its stockholders' equity of $1.412 million as of June 30, 2026, fell below the Nasdaq minimum requirement of $2.5 million. The company believes it has since regained compliance as of July 31, 2026, through liability reductions, though Nasdaq will continue to monitor the company's status until its next periodic report.
Surgery Partners Divestiture to Intermountain Health for $797M
Surgery Partners, Inc. completed the sale of its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $796.6 million. The company intends to use the proceeds primarily to pay down existing debt. The transaction closed following the satisfaction of conditions, including physician approvals.
Aflac Insider Japan Post Holdings Co. Ltd. Sells $1.6M of Stock
Japan Post Holdings Co. Ltd. sold 13,600 shares of Aflac Inc at $116.84 to $117.55 a share (average $117.34) in 2 transactions, worth $1.6M in total on Sep 15, 2026. Shares held after the trade: 50,570,990 (-0.0%).
TuHURA Biosciences adopted the 2026 Inducement Equity Incentive Plan, reserving 5,000,000 shares of common stock for equity awards to new employees. The plan is designed to provide material inducements for new hires and was adopted without stockholder approval in accordance with Nasdaq Listing Rule 5635(c)(4).
Borr Drilling Insider Tor Olav Troim Buys $4.3M of Stock
Tor Olav Troim bought 1,000,000 shares of Borr Drilling Ltd at $4.30 a share, worth $4.3M in total on Sep 16, 2026. Shares held after the trade: 30,385,941 (+3.4%).
Eightco Holdings provided a treasury and portfolio update reporting total holdings of approximately $380 million as of September 16, 2026. The holdings include $120 million in cash/stablecoins, 16,278 ETH, 302 million WLD tokens, and indirect equity stakes in OpenAI and Beast Industries.
Jerome S. Baglien, the company's CFO and COO, has been appointed as President effective September 16, 2026. He succeeds Michael Comparato, who resigned as CEO and President on September 15, 2026, but will remain an advisor to the company's external advisor.
Franklin BSP Real Estate Debt, Inc. appointed Jerome S. Baglien as President, effective September 16, 2026, in addition to his roles as CFO and COO. He succeeds Michael Comparato, who resigned as CEO, President, and Director on September 15, 2026, though he will remain an advisor to the company's external advisor.
Franklin BSP Realty Trust announced that Richard J. Byrne has been reappointed as Chief Executive Officer, succeeding Michael Comparato who resigned to spend more time with his family. Additionally, Jerome S. Baglien was appointed Co-President while retaining his roles as CFO and COO, and Brian Buffone was also named Co-President.
Duke Robotics Corp. appointed Avi Levin as Chief Financial Officer, effective October 1, 2026, succeeding Shlomo Zakai. Mr. Levin's compensation package includes a monthly base salary of approximately $17,227, an annual performance bonus of up to eight monthly salaries, and the future grant of 35,000 stock options vesting over three years.
Envista Holdings Corporation is hosting its 2026 Investor Day on September 17, 2026. During the event, executive leadership will present the company's long-term strategy, innovation priorities, and financial objectives to analysts and investors.
Star Bulk Carriers COO Nikolaos Reskos Buys $283K of Stock
Nikolaos Reskos, COO, bought 10,000 shares of Star Bulk Carriers Corp. at $28.27 a share, worth $283K in total on Sep 15, 2026. Shares held after the trade: 410,875 (+2.5%).
Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data in the International Journal of Molecular Sciences demonstrating that Telomir-Zn restored visual function and retinal structure in a model of age-related macular degeneration (AMD). The study showed that 14 days of oral treatment significantly improved visual performance, reduced mitochondrial oxidative stress, and increased telomeric DNA content. While the company remains focused on its Phase 1/2 clinical trial for triple-negative breast cancer, these findings suggest the drug's metal-dependent epigenetic biology may have broader applications beyond oncology.
bioAffinity Technologies announced that the Hong Kong Intellectual Property Department has granted a patent (HK40048460) for its CyPath Lung diagnostic technology. This patent, alongside a previously granted Chinese patent, strengthens the company's intellectual property position in the Asian market, which accounts for nearly two-thirds of global lung cancer cases.
MIRA Pharmaceuticals has advanced its Ketamir-2 Phase 2a clinical program for chemotherapy-induced peripheral neuropathy (CIPN) toward site initiation following a protocol review by the FDA. The company has incorporated the regulator's feedback and submitted the protocol for Institutional Review Board (IRB) review, with site initiation targeted for the first quarter of 2027.
Colony Bankcorp Signs $163M M&A Deal with First Reliance Bancshares, Inc.
Colony Bankcorp announced it has received all required regulatory approvals for its previously announced $163 million acquisition of First Reliance Bancshares. The merger, which will create a combined institution with approximately $5 billion in assets, is expected to close on November 1, 2026, pending shareholder approvals.
Clarivate $75M Debt Financing with Clarivate Science Holdings Corporation
Clarivate Plc's subsidiary, Clarivate Science Holdings Corporation, has commenced a cash tender offer to repurchase up to $75 million in aggregate principal amount of its 3.875% Senior Secured Notes due 2028. The offer is part of a debt management strategy with the total consideration to be determined based on a fixed spread over a reference U.S. Treasury security yield.
Littelfuse entered into an amended share purchase and supply agreement with Elmos Semiconductor SE regarding its previously acquired 200mm wafer fab in Dortmund, Germany. The amendment simplifies legacy contractual arrangements and increases strategic flexibility for the asset in exchange for a one-time fee of €24.6 million. This update follows the original acquisition and capacity-sharing arrangement announced in 2023 and 2024.
HyOrc Debt Financing Update with GS Capital Partners, LLC
HyOrc Corporation entered into an amendment with GS Capital Partners to extend the maturity date of a $150,000 promissory note from September 2026 to March 2027. In exchange for the extension, the principal balance was increased to $165,000, and 250,000 previously returnable shares held by the lender will now be retained permanently by GS Capital.
World Kinect Corporation announced that co-founder Michael J. Kasbar will step down as Executive Chairman effective December 31, 2026. The Board has appointed independent director Ken Bakshi to succeed him as Chairman of the Board on the same date. Mr. Kasbar will remain a member of the Board and will receive severance benefits as per his previous employment agreement.
Freedom Holding Corp. held its 2026 Annual Meeting of Stockholders on September 16, 2026. Shareholders elected Askar Tashtitov and Boris Cherdabayev as Class I directors, approved executive compensation on an advisory basis, and ratified Deloitte LLP as the independent accounting firm for fiscal year 2027.
Hallador Energy $675M Debt Financing with Kennedy Lewis Investment Management LLC
Hallador Energy entered into a $600 million senior secured term loan facility with Kennedy Lewis Investment Management and established the ability to add a $75 million super-priority revolving credit facility. The proceeds will primarily fund the development and construction of the company's 460-megawatt Turtle Creek Gas project, as well as the repayment of $120 million in existing debt.
Aethlon Medical Signs $150M M&A Deal with North Immunology, Inc.
Aethlon Medical (AEMD) has entered into a definitive agreement to acquire North Immunology in an all-stock merger transaction valued at a framework of $150 million for the target. Concurrent with the merger, North Immunology secured an oversubscribed $180 million private placement from a syndicate of healthcare investors to fund operations into 2028. The combined company will focus on advancing NOR-101, a bispecific antibody for atopic dermatitis, and will trade under the new ticker NRTX.